Does the media refer more to MANE or COLL?

In the previous week, Collegium Pharmaceutical had 20 more articles in the media than Veradermics. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 3 mentions for Veradermics. Collegium Pharmaceutical's average media sentiment score of 0.21 beat Veradermics' score of -0.21 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer OGN or COLL?

In the previous week, Collegium Pharmaceutical had 20 more articles in the media than Organon & Co.. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.68 beat Collegium Pharmaceutical's score of 0.21 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral

Collegium Pharmaceutical (COLL) Competitors

$29.47 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$29.53 +0.06 (+0.20%)

As of 08:32 AM Eastern

Compare

COLL vs. DFTX, MANE, EWTX, CPRX, and OGN

Should you buy Collegium Pharmaceutical stock or one of its competitors? MarketBeat compares Collegium Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Collegium Pharmaceutical include Definium Therapeutics (DFTX), Veradermics (MANE), Edgewise Therapeutics (EWTX), Catalyst Pharmaceuticals (CPRX), and Organon & Co. (OGN). These companies are all part of the "pharmaceuticals" industry.

How does Collegium Pharmaceutical compare to Definium Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Collegium Pharmaceutical has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.23	$62.87M	$1.24	23.77
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Collegium Pharmaceutical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 6 more articles in the media than Definium Therapeutics. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 17 mentions for Definium Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.21 beat Definium Therapeutics' score of -0.07 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Definium Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Collegium Pharmaceutical presently has a consensus target price of $52.60, indicating a potential upside of 78.49%. Definium Therapeutics has a consensus target price of $55.00, indicating a potential upside of 19.20%. Given Collegium Pharmaceutical's higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00

27.9% of Definium Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 5.93% compared to Definium Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Definium Therapeutics	N/A	-84.01%	-63.66%

Summary

Collegium Pharmaceutical beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Veradermics?

Veradermics (NYSE:MANE) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Collegium Pharmaceutical had 20 more articles in the media than Veradermics. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 3 mentions for Veradermics. Collegium Pharmaceutical's average media sentiment score of 0.21 beat Veradermics' score of -0.21 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 34.86%. Collegium Pharmaceutical has a consensus target price of $52.60, suggesting a potential upside of 78.49%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Collegium Pharmaceutical has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.32	N/A
Collegium Pharmaceutical	$780.57M	1.23	$62.87M	$1.24	23.77

Collegium Pharmaceutical has a net margin of 5.93% compared to Veradermics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Summary

Collegium Pharmaceutical beats Veradermics on 12 of the 13 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Collegium Pharmaceutical (NASDAQ:COLL) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Collegium Pharmaceutical has a net margin of 5.93% compared to Edgewise Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Collegium Pharmaceutical has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.23	$62.87M	$1.24	23.77
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 18 mentions for Edgewise Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.21 beat Edgewise Therapeutics' score of -0.24 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Collegium Pharmaceutical currently has a consensus price target of $52.60, suggesting a potential upside of 78.49%. Edgewise Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 12.02%. Given Collegium Pharmaceutical's higher probable upside, equities research analysts plainly believe Collegium Pharmaceutical is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Collegium Pharmaceutical beats Edgewise Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Catalyst Pharmaceuticals?

Collegium Pharmaceutical (NASDAQ:COLL) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Collegium Pharmaceutical's net margin of 5.93%. Collegium Pharmaceutical's return on equity of 91.43% beat Catalyst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Collegium Pharmaceutical had 22 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 1 mentions for Catalyst Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 0.21 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Collegium Pharmaceutical. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.23	$62.87M	$1.24	23.77
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Collegium Pharmaceutical presently has a consensus price target of $52.60, indicating a potential upside of 78.49%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.62%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Summary

Catalyst Pharmaceuticals beats Collegium Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Collegium Pharmaceutical has a net margin of 5.93% compared to Organon & Co.'s net margin of 3.41%. Collegium Pharmaceutical's return on equity of 91.43% beat Organon & Co.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 16.15%. Collegium Pharmaceutical has a consensus price target of $52.60, suggesting a potential upside of 78.49%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Collegium Pharmaceutical had 20 more articles in the media than Organon & Co.. MarketBeat recorded 23 mentions for Collegium Pharmaceutical and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.68 beat Collegium Pharmaceutical's score of 0.21 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Organon & Co. has higher revenue and earnings than Collegium Pharmaceutical. Organon & Co. is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.77	17.66
Collegium Pharmaceutical	$780.57M	1.23	$62.87M	$1.24	23.77

Summary

Collegium Pharmaceutical beats Organon & Co. on 12 of the 17 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$959.54M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	23.77	790.98	270.62	25.05
Price / Sales	1.23	971.35	659.52	107.93
Price / Cash	1.94	15.12	28.89	37.44
Price / Book	3.09	10.38	11.20	6.43
Net Income	$62.87M	$2.78B	$3.45B	$348.10M
7 Day Performance	-17.17%	2.82%	3.40%	2.66%
1 Month Performance	-16.35%	-0.59%	-0.72%	-0.85%
1 Year Performance	-15.63%	192.60%	77.41%	23.96%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	2.9889 of 5 stars	$29.47 flat	$52.60 +78.5%	-15.6%	$959.54M	$780.57M	23.77	210	Earnings Report Analyst Forecast High Trading Volume
DFTX Definium Therapeutics	3.0108 of 5 stars	$41.79 -4.0%	$54.85 +31.2%	+368.4%	$4.34B	N/A	N/A	40	Earnings Report Analyst Forecast
MANE Veradermics	2.2141 of 5 stars	$100.97 -3.8%	$153.00 +51.5%	N/A	$4.22B	N/A	N/A	19	Gap Down High Trading Volume
EWTX Edgewise Therapeutics	2.1351 of 5 stars	$38.38 -0.1%	$48.75 +27.0%	+243.2%	$4.13B	N/A	N/A	60	News Coverage Positive News Earnings Report Analyst Revision
CPRX Catalyst Pharmaceuticals	3.0906 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. DFTX, MANE, EWTX, CPRX, and OGN

How does Collegium Pharmaceutical compare to Definium Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Veradermics?

Summary

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Summary

How does Collegium Pharmaceutical compare to Catalyst Pharmaceuticals?

Summary

How does Collegium Pharmaceutical compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. DFTX, MANE, EWTX, CPRX, and OGN

How does Collegium Pharmaceutical compare to Definium Therapeutics?

Which has higher earnings and valuation, COLL or DFTX?

Which has more volatility and risk, COLL or DFTX?

Does the media refer more to COLL or DFTX?

Do analysts prefer COLL or DFTX?

Do institutionals and insiders believe in COLL or DFTX?

Is COLL or DFTX more profitable?

Summary

How does Collegium Pharmaceutical compare to Veradermics?

Does the media refer more to MANE or COLL?

Do analysts recommend MANE or COLL?

Which has higher earnings and valuation, MANE or COLL?

Is MANE or COLL more profitable?

Summary

How does Collegium Pharmaceutical compare to Edgewise Therapeutics?

Is COLL or EWTX more profitable?

Which has stronger valuation and earnings, COLL or EWTX?

Does the media prefer COLL or EWTX?

Which has more volatility and risk, COLL or EWTX?

Do analysts prefer COLL or EWTX?

Summary

How does Collegium Pharmaceutical compare to Catalyst Pharmaceuticals?

Which has more volatility & risk, COLL or CPRX?

Is COLL or CPRX more profitable?

Do institutionals & insiders have more ownership in COLL or CPRX?

Does the media refer more to COLL or CPRX?

Which has better valuation and earnings, COLL or CPRX?

Do analysts prefer COLL or CPRX?

Summary

How does Collegium Pharmaceutical compare to Organon & Co.?

Is OGN or COLL more profitable?

Do insiders and institutionals have more ownership in OGN or COLL?

Do analysts recommend OGN or COLL?

Does the media prefer OGN or COLL?

Which has more risk and volatility, OGN or COLL?

Which has better earnings & valuation, OGN or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools